PROGNOSTIC VALUE OF PRE-RADIOTHERAPY FDG-PET IN ADVANCED HODGKIN' S DISEASE TREATED BY BEACOPP CHEMOTHERAPY REGIMEN

被引：0
|
作者：
Chiesa, S. [1 ]
De Santis, M. C. [1 ]
Teofili, L. [2 ]
Manfrida, S. [1 ]
Vannata, B. [2 ]
Frascino, V. [1 ]
Fiorentino, A. [1 ]
Calcagni, L. [3 ]
Hohaus, S. [2 ]
Balducci, M. [1 ]
机构：
[1] Catholic Univ, Policlin Univ A Gemelli, Radiol Dept, Rome, Italy
[2] Catholic Univ, Policlin Univ A Gemelli, Haematol & Oncol Day Unit, Rome, Italy
[3] Catholic Univ, Policlin Univ A Gemelli, Nucl Med, Rome, Italy
来源：
RADIOTHERAPY AND ONCOLOGY | 2010年 / 94卷
关键词：
D O I：
10.1016/S0167-8140(15)34534-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
115
引用
收藏
页码：S44 / S45
页数：2
相关论文
共 50 条
  • [1] BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
    Diehl, V
    Sieber, M
    Ruffer, U
    Lathan, B
    Hasenclever, D
    Pfreundschuh, M
    Loeffler, M
    Lieberz, D
    Koch, P
    Adler, M
    Tesch, H
    ANNALS OF ONCOLOGY, 1997, 8 (02) : 143 - 148
  • [2] Early FDG-PET scan in advanced stage Hodgkin lymphoma treated with BEACOPP-14
    Rubio-Martinez, A.
    Alvarez, R.
    Garcia-Miralles, M.
    Gaston, R.
    Giraldo, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 471 - 472
  • [3] BEACOPP:: A new regimen for advanced Hodgkin's disease
    Diehl, V
    Franklin, J
    Hasenclever, D
    Tesch, H
    Pfreundschuh, M
    Lathan, B
    Paulus, U
    Sieber, M
    Rüffer, JU
    Sextro, M
    Engert, A
    Wolf, J
    Hermann, R
    Holmer, L
    Stappert-Jahn, U
    Winnerlein-Trump, E
    Wulf, G
    Krause, S
    Glunz, A
    von Kalle, K
    Bischoff, H
    Haedicke, C
    Dühmke, E
    Georgii, A
    Loeffler, M
    ANNALS OF ONCOLOGY, 1998, 9 : 67 - 71
  • [4] Interim FDG-PET does not predict outcome in advanced-stage Hodgkin lymphoma patients treated with BEACOPP
    Adams, Hugo J. A.
    Kwee, Thomas C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (04) : 758 - 760
  • [5] Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (06) : 491 - 498
  • [6] The role of FDG-PET in early therapy assessment and follow-up of patients with advanced Hodgkin Lymphoma treated with BEACOPP
    Kahraman, D.
    Markova, J.
    Kobe, C.
    Skopalova, M.
    Mocikova, H.
    Klaskova, K.
    Dedeckova, K.
    Eich, H.
    Boell, B.
    Dietlein, M.
    Kozak, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S251 - S251
  • [7] Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
    Hutchings, M
    Mikhaeel, NG
    Fields, PA
    Nunan, T
    Timothy, AR
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1160 - 1168
  • [8] Prognostic value of interim FDG-PET in Hodgkin lymphoma (HL) after 4 courses of chemotherapy
    Le Roux, Pierre
    Bodet-Milin, Caroline
    Gastinne, Thomas
    Querellou, Solene
    Rousseau, Caroline
    Le Gouill, Steven
    Salaun, Pierre
    Bodere-Kraeber, Francoise
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [9] Population pharmacokinetics of drugs in the BEACOPP chemotherapy regimen used in Hodgkin's disease
    Wilde, S
    Jetter, A
    Menzel, H
    Rietbrock, S
    Zaigler, M
    Sieber, M
    Tesch, H
    Hempel, G
    Reif, S
    Jaehde, U
    Merkel, U
    Johnson, S
    Diehl, V
    Fuhr, U
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (03) : 147 - 149
  • [10] The value of dual point interim FDG-PET/CT assessment in a patient with advanced Hodgkin's lymphoma (HL) with bulky masses treated with ABVD chemotherapy
    Zaucha, J.
    Malkowski, B.
    Gallamini, A.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S27 - S28
12345